A Phase II test of AK146D1 with AK112 in advanced NSCLC

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a Phase II interventional trial evaluating safety, tolerability, pharmacokinetics, and antitumor activity of AK146D1 in combination with AK112 or other anticancer therapies for adults with locally advanced or metastatic NSCLC who are not candidates for curative treatment. Eligible participants are 18 to 75 years old with ECOG 0-1 and measurable disease per RECIST 1.1, and adequate organ function. The study may include AK146D1 and AK112 injections, platinum-based chemotherapy, and Osimertinib as treatment components. The trial is conducted at Sun Yat-sen University Cancer Center in Guangzhou, with Akeso as the lead sponsor.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Be able to understand and voluntarily sign the written informed consent form.
2. Aged of ≥ 18 years and ≤75 years.
3. ECOG PS 0 or 1.
4. The expected lifespan is ≥3 months.
5. Patients with histologically or cytologically confirmed locally advanced (Stage IIIB/IIIC) or metastatic (Stage IV) non-small cell lung cancer (NSCLC) who are not eligible for curative surgical resection and cannot receive definitive concurrent or sequential chemoradiotherapy.
6. At least one measurable non-brain lesion according to RECIST v1.1.
7. Have sufficient organ function.
8. Females subjects must not be pregnant at screening or have evidence of non-childbearing potential. Agree to use medically accepted methods of contraception.

Exclusion Criteria:

1. NSCLC mixed with a component of small cell lung cancer, neuroendocrine carcinoma, or carcinosarcoma.
2. Having other active malignancies within 3 years.
3. Currently participating in another interventional clinical study.
4. Presence of active metastases to the central nervous system. For patients with asymptomatic brain metastasis or stable symptoms after treatment can be included.
5. Having received any treatment targeting Trop2 or Nectin4.
6. Prior chemotherapy or antibody-drug conjugate (ADC) therapy targeting topoisomerase I inhibitors.
7. Receipt of systemic anti-tumor therapy (including chemotherapy, immunotherapy, biological agents, etc.) within 4 weeks (or 5 half-lives of the drug, whichever is longer) prior to the first dose.
8. Toxicity of previous antineoplastic therapy has not resolved to NCI CTCAE 6.0 grade 1 or lower.
9. Subjects with clinically significant cardiovascular or cerebrovascular diseases or risks.
10. Subjects with active autoimmune diseases requiring systemic treatment within 2 years.
11. Receipt of systemic anti-infective therapy within 2 weeks prior to the first dose.
12. Known to be positive for HIV and other infections.
13. Previous history of severe hypersensitivity reactions.
14. Live attenuated vaccines were received within 4 weeks.
15. Subjects with a history of mental illness and incapacitated or limited capacity.
16. Any disease or condition that, in the opinion of the investigator, would compromise subject safety or interfere with study assessments.

Where it's running

• SunYat-sen University Cancer Center
  Guangzhou, Guangdong, China Recruiting

Study contacts

• Study coordinator: Ting Liu
• Email: clinicaltrials@akesobio.com
• Phone: +86(0760)8987 3999

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Befotertinib plus chemo with MRD-guided escalation for EGFR-mutant NSCLC

  This phase 2 trial tests whether starting befotertinib and then using MRD results to guide adding chemotherapy improves outcomes for adults with EGFR-mutant advanced NSCLC.

  Recruiting Phase 2 Guangzhou University of Traditional Chinese Medicine · Guangzhou, Guangdong and 1 other locations · NCT07709585

• Liquid biopsy at diagnosis for advanced NSCLC

  We’re testing whether a blood test (liquid biopsy) done early can speed up getting usable molecular information for adults with suspected advanced NSCLC.

  Recruiting Regina Elena Cancer Institute · Roma, RM · NCT07649629

• AMT-116 with AK112 in advanced NSCLC

  This study tests whether AMT-116 plus Ivonescimab (AK112) is safe and helpful for adults with advanced non-small cell lung cancer who can’t be cured with surgery or standard treatment.

  Recruiting Phase 1/2 Multitude Therapeutics Inc. · Guangzhou, Guangdong and 1 other locations · NCT07590531

• Finding better ways to detect resistance to antibody‑drug conjugates in solid tumors and identify useful biomarkers

  This trial tests whether tissue and blood biomarkers collected before and after treatment can reveal why antibody‑drug conjugates stop working in adults with advanced breast, gastric, urothelial, or non‑small cell lung cancer.

  Recruiting Phase 2 Unicancer · Villejuif · NCT07259226

• BC008-1A for advanced esophageal cancer and non-small cell lung cancer

  This study will try giving BC008-1A by IV every three weeks to see if it is safe and helps people with advanced esophageal cancer or non-small cell lung cancer with PD‑L1 expression.

  Recruiting Phase 1 Sichuan Luzhou Buchang Biopharmaceutical Co., Ltd. · Tianjin · NCT06773507

• Vorolanib treatment for advanced non-small cell lung cancer patients

  This study is testing if Vorolanib can help patients with advanced non-small cell lung cancer who have already tried other treatments feel better and live longer.

  Recruiting Phase 2 Sun Yat-sen University · Guangzhou, Guangdong · NCT06728852

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.